UBX1325 (foselutoclax)
Diabetic Macular Edema (DME)
Key Facts
About Unity Biotechnology
Unity Biotechnology was founded on groundbreaking academic research into cellular senescence as a root cause of age-related diseases. Its mission was to develop selective senolytic medicines, initially focusing on localized delivery for ophthalmologic conditions like diabetic macular edema and neurodegenerative diseases. Despite promising early-stage clinical data and raising significant capital, the company faced clinical setbacks, pivoted its strategy, and ultimately ceased operations in 2024, marking the end of a prominent early player in the longevity therapeutics field.
View full company profileAbout Unity Biotechnology
Unity Biotechnology was founded on groundbreaking academic research into cellular senescence as a root cause of age-related diseases. Its mission was to develop selective senolytic medicines, initially focusing on localized delivery for ophthalmologic conditions like diabetic macular edema and neurodegenerative diseases. Despite promising early-stage clinical data and raising significant capital, the company faced clinical setbacks, pivoted its strategy, and ultimately ceased operations in 2024, marking the end of a prominent early player in the longevity therapeutics field.
View full company profileTherapeutic Areas
Other Diabetic Macular Edema (DME) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLS-AX | Clearside Biomedical | Preclinical |
| OCS-01 | Oculis | Phase 3 |
| Oral K9 | Inflammasome Therapeutics | Phase I |
| Allgenesis Phase 2 DME Trial Support | Voxeleron | Phase 2 |
| Avoralstat | BioCryst Pharmaceuticals | Phase 2 |
| DURAVYU™ (EYP-1901) | EyePoint Pharmaceuticals | Phase 3 |
| Sozinibercept (OPT-302) | Opthea | Phase 2 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg) | Outlook Therapeutics | Phase 3 |